Publication date: Mar 20, 2019
March 19, 2019 – Intermountain Healthcare and Geisinger Health System have each received recognition for their work in advancing precision medicine and improving patient care.
READ MORE: Precision Medicine Partnership Aims to Curb Adverse Drug Events -Genomic screening for ARVC offers an opportunity to identify patients at risk for sudden cardiac death prior to the presentation of symptoms,” said Christopher Haggerty, PhD, principal investigator of the study and an assistant professor in Geisinger’s Department of Imaging Science and Innovation.
For someone at risk of sudden cardiac death, this type of ‘precision medicine’ approach could save his or her life, giving us great hope that this research will provide the insights necessary to achieve this goal. “
READ MORE: Precision Medicine Approach Reduces Heart Failure Mortality by 50% -The MyCode Genomic Screening and Counseling team is thrilled to be working with Dr. Haggerty on this innovative and important study,” said Amy Sturm, LGC, a study co-investigator and leader of the MyCode Genomic Screening and Counseling Program, as well as director of Cardiovascular Genomic Counseling at Geisinger.
-Our genetic counseling team works with individuals receiving these ARVC risk results from MyCode, as well as their at-risk family members, and the findings of this study will be key to the type of counseling, anticipatory guidance and preventive recommendations we provide. “
-Precision medicine has opened doors that have allowed us to make a real impact on numerous people in the communities we serve,” said Lincoln Nadauld, MD, chief of precision health for Intermountain Healthcare.
Intermountain’s large biorepository will serve to enhance precision medicine efforts, storing more than three million tissue samples for research and cancer care.
|disease||MESH||arrhythmogenic right ventricular cardiomyopathy|
|disease||DOID||arrhythmogenic right ventricular cardiomyopathy|
|pathway||BSID||Arrhythmogenic Right Ventricular Cardiomyopathy|
|disease||MESH||Adverse Drug Events|
|disease||MESH||sudden cardiac death|
- Genetic and non-genetic determinants of clinical phenotypes in cardiomyopathy.
- Implementing Precision Medicine in Community-Based Oncology Programs: Three Models.
- Genetic counseling for consumer-driven whole exome and whole genome sequencing: A commentary on early experiences.
- How artificial intelligence could redefine clinical trials in cardiovascular medicine: lessons learned from oncology.